Pfizer New Haven Clinical Research Unit Celebrates 10 Year Anniversary

Study Graphic

At the Pfizer Clinical Research Unit (CRU) anniversary event, Mikael Dolsten, M.D., Ph.D., President of Worldwide Research and Development noted that the CRU conducts studies on potential medicines in core areas where Pfizer believes it is best positioned to bring unique, potential therapies to patients with unmet medical need. These areas include chronic inflammatory and autoimmune diseases, cardiovascular and metabolic disease, oncology, neuroscience and pain, rare diseases and vaccines. Many of the medicines studied in the CRU clinical trial are now approved and available to patients.